TTK Healthcare Ltd
₹ 1,266
-0.39%
02 Jun
- close price
- Market Cap ₹ 1,789 Cr.
- Current Price ₹ 1,266
- High / Low ₹ 1,474 / 667
- Stock P/E 40.1
- Book Value ₹ 657
- Dividend Yield 0.79 %
- ROCE 19.0 %
- ROE 13.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 19.7% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 18.2%
- Debtor days have improved from 35.2 to 27.0 days.
Cons
- The company has delivered a poor sales growth of 4.66% over past five years.
- Company has a low return on equity of 13.6% over last 3 years.
- Earnings include an other income of Rs.643 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Diversified Industry: Diversified - Medium / Small
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
354 | 382 | 416 | 483 | 519 | 528 | 578 | 628 | 646 | 476 | 599 | 725 | |
330 | 362 | 396 | 453 | 478 | 489 | 535 | 578 | 617 | 457 | 577 | 694 | |
Operating Profit | 24 | 20 | 20 | 30 | 40 | 38 | 43 | 50 | 28 | 19 | 22 | 31 |
OPM % | 7% | 5% | 5% | 6% | 8% | 7% | 7% | 8% | 4% | 4% | 4% | 4% |
5 | 7 | 6 | 7 | 6 | 6 | 8 | 8 | 9 | 28 | 42 | 643 | |
Interest | 3 | 3 | 3 | 4 | 3 | 3 | 5 | 3 | 3 | 2 | 3 | 5 |
Depreciation | 2 | 3 | 3 | 6 | 7 | 12 | 15 | 15 | 14 | 13 | 13 | 13 |
Profit before tax | 24 | 22 | 20 | 26 | 36 | 29 | 30 | 39 | 19 | 32 | 48 | 657 |
Tax % | 34% | 34% | 37% | 39% | 36% | 36% | 40% | 38% | 37% | -44% | 13% | 3% |
Net Profit | 16 | 14 | 12 | 16 | 23 | 19 | 18 | 24 | 12 | 46 | 42 | 640 |
EPS in Rs | 20.13 | 18.28 | 15.95 | 20.81 | 29.19 | 24.13 | 12.86 | 17.25 | 8.72 | 32.87 | 29.43 | 452.72 |
Dividend Payout % | 20% | 22% | 25% | 22% | 17% | 21% | 39% | 29% | 34% | 18% | 34% | 2% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 5% |
3 Years: | 4% |
TTM: | 21% |
Compounded Profit Growth | |
---|---|
10 Years: | 13% |
5 Years: | 20% |
3 Years: | 53% |
TTM: | 13% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | 10% |
3 Years: | 45% |
1 Year: | 74% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 11% |
3 Years: | 14% |
Last Year: | 14% |
Balance Sheet
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
8 | 8 | 8 | 8 | 8 | 8 | 14 | 14 | 14 | 14 | 14 | 14 | |
Reserves | 80 | 90 | 99 | 110 | 128 | 150 | 219 | 237 | 235 | 281 | 316 | 914 |
18 | 22 | 32 | 42 | 38 | 23 | 47 | 29 | 30 | 19 | 22 | 24 | |
86 | 89 | 102 | 115 | 128 | 104 | 127 | 136 | 152 | 180 | 207 | 286 | |
Total Liabilities | 192 | 209 | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,238 |
33 | 43 | 54 | 52 | 106 | 99 | 110 | 98 | 89 | 85 | 80 | 75 | |
CWIP | 6 | 0 | 2 | 46 | 1 | 0 | 1 | 2 | 9 | 0 | 0 | 1 |
Investments | 7 | 1 | 0 | 0 | 10 | 9 | 9 | 13 | 9 | 13 | 15 | 226 |
146 | 165 | 184 | 177 | 185 | 177 | 288 | 304 | 325 | 395 | 463 | 936 | |
Total Assets | 192 | 209 | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,238 |
Cash Flows
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | 24 | 13 | 39 | 37 | 18 | 25 | 17 | 20 | 96 | 45 | ||
-4 | -1 | -15 | -49 | -27 | 5 | -22 | 10 | -13 | -77 | -31 | ||
-1 | -2 | 2 | 3 | -11 | -23 | -7 | -31 | -10 | -17 | -9 | ||
Net Cash Flow | 1 | 22 | 0 | -7 | -0 | 0 | -4 | -4 | -4 | 2 | 5 |
Ratios
Figures in Rs. Crores
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 39 | 34 | 34 | 34 | 33 | 24 | 35 | 47 | 43 | 46 | 33 | |
Inventory Days | 64 | 52 | 64 | 62 | 66 | 65 | 80 | 77 | 101 | 123 | 102 | |
Days Payable | 70 | 55 | 56 | 50 | 53 | 100 | 130 | 101 | 121 | 170 | 134 | |
Cash Conversion Cycle | 32 | 31 | 41 | 46 | 46 | -11 | -16 | 22 | 23 | -2 | 1 | |
Working Capital Days | 1 | -8 | -12 | -14 | -22 | -9 | -1 | 10 | 13 | -18 | -15 | |
ROCE % | 27% | 21% | 17% | 20% | 23% | 18% | 15% | 15% | 8% | 9% | 15% |
Documents
Announcements
- Disclosure Regarding Communication To Physical Shareholders Of The Company Pursuant To SEBI Circular Dated March 16 2023 30 May
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
26 May - In accordance with SEBI Circular No.CIR/CFD/CMD1/27/2019 dated 8th February, 2019, we are forwarding herewith the Secretarial Compliance Report dated 12th May, 2023, for the financial …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24 May - Disclosure under Regulation 30 - Publication of Audited Financial Results along with Audit Report for the Fourth Quarter and Year ended 31st March, 2023.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 24 May
- Declaration Of Voting Results Of The Postal Ballot By Remote E-Voting Process In Accordance With The Regulation 44(3) Of The SEBI (LODR) Regulations, 2015, As Amended (The 'Listing Regulations'), The SEBI (Delisting Of Equity Shares) Regulations, 2021 (The 'Delisting Regulations') And Submission Of Scrutinizer'S Report. 23 May
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Sep 2016TranscriptNotesPPT
Pharmaceuticals Business
The company's pharmaceuticals business includes products for both human and veterinary use: